MIR6797

Across TCGA pan-cancer cohorts, MIR6797 RNA differs between tumor and matched normal tissue in 13 of 18 cancer types tested, making tumor–normal expression one of MIR6797’s most consistent transcriptional readouts.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where MIR6797 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types MIR6797 is over-expressed in tumor, although a few such as KICH show the opposite, repressed pattern.

BLCA, KIRC, and STAD are the cancer types where MIR6797 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in MIR6797 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
BLCA	Male	III,IV	+1.791	<.001	10	view →
KIRC	Male	All	+0.479	<.001	9	view →
STAD	All	II,III,IV	+0.994	<.001	8	view →
LUAD	Female	All	+0.870	<.001	7	view →
UCEC	All	IV	+2.375	.004	6	view →
COAD	Female	II,III,IV	+1.284	<.001	6	view →
READ	Female	All	+1.953	<.001	5	view →
KIRP	Female	II,III,IV	+1.482	.007	5	view →
LUSC	Male	II,III,IV	+1.403	<.001	5	view →
CHOL	All	All	+1.976	<.001	3	view →
BRCA	All	All	+0.330	.004	2	view →
KICH	Female	III,IV	−1.059	.033	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 13 lineages.

MIR6797–BLCA

Open the BLCA breakdown →